Cleo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cleo Lee has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
William Jia
4 shared publicationsKevin Zhang
3 shared publicationsPaul S. Rennie
3 shared publicationsYoshiyuki Matsui
Kyoto, Japan
3 shared publicationsAlan I. So
The Vancouver Prostate Centre and Department of Urology, Vancouver, British Columbia, Canada
2 shared publicationsJohn C. Bell
Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
2 shared publications
Latest Publications
- 1 June 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 13 (9) , 1786-1794
Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Herpes simplex virus (HSV) is a well-known vector that is often used for gene therapy to treat cancers. The most attractive feature of HSV is its ability to destroy tumors through a distinctive oncolytic mechanism where the virus can destroy cancer cells via cell lysis, a killing function that no anti-cancer drugs can mimic. Importantly, HSV is a safe and effective virus that can be easily manipulated to preferentially replicate in tumor cells. In the last 20 years of reengineering efforts, a number of HSV designs, including the classical G207, have been focused on deleting viral genes in order to render the virus tumor specific. Although such designs can successfully destroy tumor xenografts in animal models, with minimal impact on normal tissues, a common trade-off is the marked attenuation of the virus. This problem is most profound in many clinical tumors, where virus dissemination is often hindered by the difficult cellular and molecular terrain of the human tumor mass. In order to harness all of HSV’s replication potential to destroy tumor cells, efforts in our lab, as well as others, last several years have been focused on engineering an oncolytic HSV to target tumor cells without deleting any viral genes, and have since generated highly tumor specific viruses including our transcriptional translational dually regulated HSV (TTDR-HSV). In this review, we will discuss the improvements associated with the newer TTDR-HSV design compared to the classical defective HSV designs such as G207 and tk- HSV. Lastly, we will review additional cellular features of aggressive tumors, such as their immense cellular heterogeneity and volatility, which may serve to hinder the dissemintation of TTDR-HSV. The challenge for future studies would be to explore how TTDRHSV could be redesigned and/or employed with combinatorial approaches to better target and destroy the heterogeneous and dynamic cell populations in the aggressive tumor mass.
- 1 June 2012
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 13 (9) , 1786-1794
Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Herpes simplex virus (HSV) is a well-known vector that is often used for gene therapy to treat cancers. The most attractive feature of HSV is its ability to destroy tumors through a distinctive oncolytic mechanism where the virus can destroy cancer cells via cell lysis, a killing function that no anti-cancer drugs can mimic. Importantly, HSV is a safe and effective virus that can be easily manipulated to preferentially replicate in tumor cells. In the last 20 years of reengineering efforts, a number of HSV designs, including the classical G207, have been focused on deleting viral genes in order to render the virus tumor specific. Although such designs can successfully destroy tumor xenografts in animal models, with minimal impact on normal tissues, a common trade-off is the marked attenuation of the virus. This problem is most profound in many clinical tumors, where virus dissemination is often hindered by the difficult cellular and molecular terrain of the human tumor mass. In order to harness all of HSV’s replication potential to destroy tumor cells, efforts in our lab, as well as others, last several years have been focused on engineering an oncolytic HSV to target tumor cells without deleting any viral genes, and have since generated highly tumor specific viruses including our transcriptional translational dually regulated HSV (TTDR-HSV). In this review, we will discuss the improvements associated with the newer TTDR-HSV design compared to the classical defective HSV designs such as G207 and tk- HSV. Lastly, we will review additional cellular features of aggressive tumors, such as their immense cellular heterogeneity and volatility, which may serve to hinder the dissemintation of TTDR-HSV. The challenge for future studies would be to explore how TTDRHSV could be redesigned and/or employed with combinatorial approaches to better target and destroy the heterogeneous and dynamic cell populations in the aggressive tumor mass.
- 6 August 2011
- Published by Springer Nature
- p. 345-360
Mechanisms of Radioresistance in Cancer Stem Cells
- 6 August 2011
- Published by Springer Nature
- p. 345-360
Mechanisms of Radioresistance in Cancer Stem Cells
- 30 April 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (4) , e540
1352 MICRORNA-MEDIATED TARGETING OF ONCOLYTIC HERPES SIMPLEX VIRUS-1 TO HIGH-RISK BLADDER CANCER
- 30 April 2011
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (4) , e540
1352 MICRORNA-MEDIATED TARGETING OF ONCOLYTIC HERPES SIMPLEX VIRUS-1 TO HIGH-RISK BLADDER CANCER
- Open Access
- 1 May 2010
- Published by Elsevier in Molecular Therapy
- Vol. 18 (5) , 929-935
Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors
- 1 May 2010
- Published by Elsevier in Molecular Therapy
- Vol. 18 (5) , 929-935
Open AccessTranscriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors
- 15 April 2010
- Published by American Association for Cancer Research (AACR)
- Vol. 70 (8) , 596
Abstract 596: Oncolytic vesicular stomatitis virus selectively kills bladder cancer cells which have a low level of type I interferon receptor
Bladder cancer is the second most common genitourinary malignancy. Current treatments options are of limited efficacy since approximately 80% of patients will develop recurrent tumors of which 20-30% evolve into more aggressive, potentially lethal cancers. A new strategy to treat bladder cancer is the intra-vesical application of vesicular stomatitis virus (VSV), which is a replication competent oncolytic virus that relies on an aberrant interferon signaling pathway within cancer cells. Using a tissue microarray composed of human bladder cancer cores and by immunohistochemistry, we observed that expression of type I interferon (IFN) receptor (IFNAR) was decreased relative to normal bladder tissue. Advanced bladder cancers had even lower expression of IFNAR. We observed that VSV preferentially targeted high grade bladder cancer cells which were resistant to type I IFN treatment. We also found that these high grade bladder cancer cells susceptible to VSV-induced lysis had low expression of IFNAR. Furthermore, siRNA knockdown of IFNAR indeed facilitated replication of VSV in cells previously resistant to VSV treatment. Consequently, intra-vesicular instillation of wildtype VSV and the Delta51M strain, which has an impaired ability to shutdown innate immunity, significantly inhibited high grade tumor growth by 98% and 90% respectively as compared to controls treated with UV-inactivated VSV. No evidence of toxicity or systemic viral infection in either group was found. In conclusion, down-regulation of IFNAR in bladder cancer may be one of the primary molecular mechanisms for clinical IFN resistance. However, this also facilitates VSV replication and oncolysis in high risk bladder cancers and provides a basis for selecting bladder cancer patients for IFN or oncolytic VSV therapy in future clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 596.
- 15 April 2010
- Published by American Association for Cancer Research (AACR)
- Vol. 70 (8) , 596
Abstract 596: Oncolytic vesicular stomatitis virus selectively kills bladder cancer cells which have a low level of type I interferon receptor
Bladder cancer is the second most common genitourinary malignancy. Current treatments options are of limited efficacy since approximately 80% of patients will develop recurrent tumors of which 20-30% evolve into more aggressive, potentially lethal cancers. A new strategy to treat bladder cancer is the intra-vesical application of vesicular stomatitis virus (VSV), which is a replication competent oncolytic virus that relies on an aberrant interferon signaling pathway within cancer cells. Using a tissue microarray composed of human bladder cancer cores and by immunohistochemistry, we observed that expression of type I interferon (IFN) receptor (IFNAR) was decreased relative to normal bladder tissue. Advanced bladder cancers had even lower expression of IFNAR. We observed that VSV preferentially targeted high grade bladder cancer cells which were resistant to type I IFN treatment. We also found that these high grade bladder cancer cells susceptible to VSV-induced lysis had low expression of IFNAR. Furthermore, siRNA knockdown of IFNAR indeed facilitated replication of VSV in cells previously resistant to VSV treatment. Consequently, intra-vesicular instillation of wildtype VSV and the Delta51M strain, which has an impaired ability to shutdown innate immunity, significantly inhibited high grade tumor growth by 98% and 90% respectively as compared to controls treated with UV-inactivated VSV. No evidence of toxicity or systemic viral infection in either group was found. In conclusion, down-regulation of IFNAR in bladder cancer may be one of the primary molecular mechanisms for clinical IFN resistance. However, this also facilitates VSV replication and oncolysis in high risk bladder cancers and provides a basis for selecting bladder cancer patients for IFN or oncolytic VSV therapy in future clinical trials. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 596.
- Open Access
- 2 December 2009
- Published by Wiley in International Journal of Cancer
- Vol. 127 (4) , 830-838
Down‐regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus‐induced cell death
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for bladder cancer and other cancers. Previously we reported that oncolytic VSV is a potent agent for intravesical treatment of high risk bladder cancer. We observed that VSV preferentially targeted bladder cancer cells resistant to type I interferon (IFN) treatment. The goal of the current study was to further elucidate the nature of the molecular defect of IFN signaling by which bladder cancer cells become susceptible to VSV infection. Using a tissue microarray composed of human bladder cancer cores, we observed that expression of type I IFN receptor (IFNAR) was decreased relative to normal bladder tissue. Advanced bladder cancers had even lower expression of IFNAR. We found that bladder cancer cells susceptible to VSV‐induced lysis had low expression of IFNAR as well. We hypothesized that down‐regulation of IFNAR in bladder cancer cells may be a molecular mechanism responsible for resistance to type I IFN treatment and sensitivity to VSV oncolysis. SiRNA knockdown of IFNAR indeed facilitated replication of VSV in cells previously resistant to VSV treatment. Blocking IFNAR with a neutralizing antibody showed a similar effect. Hence down‐regulation of IFNAR in bladder cancer may be one of the primary molecular mechanisms for clinical IFN resistance. However, this also facilitates VSV replication and oncolysis in high risk bladder cancers and provides a basis for selecting bladder cancer patients for IFN or oncolytic VSV therapy in future clinical trials.
- 2 December 2009
- Published by Wiley in International Journal of Cancer
- Vol. 127 (4) , 830-838
Open AccessDown‐regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus‐induced cell death
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for bladder cancer and other cancers. Previously we reported that oncolytic VSV is a potent agent for intravesical treatment of high risk bladder cancer. We observed that VSV preferentially targeted bladder cancer cells resistant to type I interferon (IFN) treatment. The goal of the current study was to further elucidate the nature of the molecular defect of IFN signaling by which bladder cancer cells become susceptible to VSV infection. Using a tissue microarray composed of human bladder cancer cores, we observed that expression of type I IFN receptor (IFNAR) was decreased relative to normal bladder tissue. Advanced bladder cancers had even lower expression of IFNAR. We found that bladder cancer cells susceptible to VSV‐induced lysis had low expression of IFNAR as well. We hypothesized that down‐regulation of IFNAR in bladder cancer cells may be a molecular mechanism responsible for resistance to type I IFN treatment and sensitivity to VSV oncolysis. SiRNA knockdown of IFNAR indeed facilitated replication of VSV in cells previously resistant to VSV treatment. Blocking IFNAR with a neutralizing antibody showed a similar effect. Hence down‐regulation of IFNAR in bladder cancer may be one of the primary molecular mechanisms for clinical IFN resistance. However, this also facilitates VSV replication and oncolysis in high risk bladder cancers and provides a basis for selecting bladder cancer patients for IFN or oncolytic VSV therapy in future clinical trials.
- Open Access
- 12 August 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (16) , 5126-5135
MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells
Purpose: Advanced castration-resistant prostate cancer, for which there are few treatment options, remains one of the leading causes of cancer death. MicroRNAs (miRNA) have provided a new opportunity for more stringent regulation of tumor-specific viral replication. The purpose of this study was to provide a proof-of-principle that miRNA-regulated oncolytic herpes simplex virus-1 (HSV-1) virus can selectively target cancer cells with reduced toxicity to normal tissues.
- 12 August 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (16) , 5126-5135
Open AccessMicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells
Purpose: Advanced castration-resistant prostate cancer, for which there are few treatment options, remains one of the leading causes of cancer death. MicroRNAs (miRNA) have provided a new opportunity for more stringent regulation of tumor-specific viral replication. The purpose of this study was to provide a proof-of-principle that miRNA-regulated oncolytic herpes simplex virus-1 (HSV-1) virus can selectively target cancer cells with reduced toxicity to normal tissues.
- 20 April 2007
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 14 (7) , 652-660
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells
The aim of the present study was to determine whether a prostate-specific amplicon, containing a probasin-derived promoter (ARR2PB) upstream of an essential Herpes simplex virus-1 (HSV-1) viral gene, infected-cell polypeptide 4 (ICP4), could complement an HSV-1 helper virus with this gene deleted (ICP4-) and cause lytic replication specifically in prostate cancer cells. Two amplicon constructs, CMV-ICP4 and ARR2PB-ICP4, were packaged by a replication-deficient ICP4- helper virus. The amplicon viruses could complement ICP4- helper viruses to efficiently replicate and cause cell lysis in prostate cancer cells. Intratumoral injection of LNCaP human prostate cancer xenografts with either amplicon/helper virus resulted in >75% reduction in tumor volume and serum prostate specific antigen (PSA). Histological and Q-PCR (quantitative PCR) analyses indicated that the toxicity in nontumor tissues was much lower with ARR2PB-ICP4 than with CMV-ICP4 amplicon/helper virus. In conclusion, a replication-deficient HSV-1 virus could be complemented by an amplicon virus to restore its oncolytic activity in a tissue-specific and low toxicity fashion, illustrating that this approach could be a potentially useful strategy for developing an oncolytic viral therapy for prostate cancer.
- 20 April 2007
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 14 (7) , 652-660
An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells
The aim of the present study was to determine whether a prostate-specific amplicon, containing a probasin-derived promoter (ARR2PB) upstream of an essential Herpes simplex virus-1 (HSV-1) viral gene, infected-cell polypeptide 4 (ICP4), could complement an HSV-1 helper virus with this gene deleted (ICP4-) and cause lytic replication specifically in prostate cancer cells. Two amplicon constructs, CMV-ICP4 and ARR2PB-ICP4, were packaged by a replication-deficient ICP4- helper virus. The amplicon viruses could complement ICP4- helper viruses to efficiently replicate and cause cell lysis in prostate cancer cells. Intratumoral injection of LNCaP human prostate cancer xenografts with either amplicon/helper virus resulted in >75% reduction in tumor volume and serum prostate specific antigen (PSA). Histological and Q-PCR (quantitative PCR) analyses indicated that the toxicity in nontumor tissues was much lower with ARR2PB-ICP4 than with CMV-ICP4 amplicon/helper virus. In conclusion, a replication-deficient HSV-1 virus could be complemented by an amplicon virus to restore its oncolytic activity in a tissue-specific and low toxicity fashion, illustrating that this approach could be a potentially useful strategy for developing an oncolytic viral therapy for prostate cancer.
- 1 March 2004
- Published by Elsevier in International Journal for Parasitology
- Vol. 34 (3) , 285-296
The SRS superfamily of Toxoplasma surface proteins
- 1 March 2004
- Published by Elsevier in International Journal for Parasitology
- Vol. 34 (3) , 285-296
The SRS superfamily of Toxoplasma surface proteins